Month: October 2019

Australian drugmaker Clinuvel Pharmaceuticals Ltd said on Wednesday the pricing of its recently approved treatment for a rare genetic disorder in the United States will not top its price in Europe. The drug, Scenesse, was approved by the U.S. Food and Drug Administration on Tuesday to treat erythropoietic protoporphyria (EPP), a painful disorder that causes the skin to itch, burn, and scar in some rare cases, when exposed to sunlight and some types of artificial light. Scenesse is available in Europe since 2014, where its price ranges between 70,000 euros ($76,811.00) and 100,000 euros ($109,730.00) per patient …read more […]

U.S. stock futures tumbled and the safe haven yen and the Swiss franc gained in early Asian trade on Thursday after a media report that the United States and China had made no progress in deputy-level trade talks earlier in the week. The South China Morning Post also said the Chinese delegation, headed by Vice Premier Liu He, is planning to leave Washington on Thursday after just one day of minister-level meetings, instead of an originally planned departure set for Friday. In the currency market, the yen advanced 0.3% to 107.11 to the dollar while the Swiss franc …read more […]

Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell’s pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […] …read more […]

High-level trade talks between U.S. and Chinese negotiators are slated to resume in Washington, D.C., on Thursday, providing an opportunity for both sides to make progress on a deal before the next tranche of tariffs on Chinese imports take effect. …read more […]

(Bloomberg) — Amazon.com Inc.’s top spokesman Jay Carney criticized the administration of President Donald Trump on Wednesday, questioning the patriotism and honesty of the current White House and criticizing it for trying to influence the Federal Reserve.In a 30-minute interview at the GeekWire Summit in Seattle, Carney drew distinctions between the current administration and those of former Presidents Barack Obama, George Bush and Bill Clinton. Carney used to be Obama’s press secretary and worked as a political reporter before that.“Virtually with no exception, everyone I dealt with in those administrations, whether I personally agreed or disagreed with what they thought …read more […]

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […] …read more […]

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […] …read more […]

DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […] …read more […]